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Objectives: Negative emotional valence of auditory verbal hallucinations (AVHs) in
schizophrenia can be a source of distress and is considered a strong predictor of illness
severity. Previous studies have found glutamate tomediateAVH severity in frontal and
temporal brain regions, however, they do not specifically address emotional valence of
AVH. The role of glutamate for the experience of negative- versus positive emotional
valence of AVH is therefore unknown andwas investigated in the current study.
Methods: Using magnetic resonance spectroscopy (MRS), 37 schizophrenia patients
had Glx (glutamate+glutamine) measured in the left superior temporal gyrus (STG),
and additionally in the anterior cingulate cortex (ACC) and the right STG, or in the
left inferior frontal gyrus (IFG). Self-reported emotional valence in AVHwasmeasured
with the Beliefs About Voices Questionnaire (BAVQ-R).
Results:Results from linearmixedmodels showed thatnegativeemotional valencewas
associatedwith reducedGlx levels across all fourmeasured brain regions in the frontal
and temporal lobe. More specifically, voices that were experienced to be omnipotent
(p = 0.04) and that the patients attempted to resist (p = 0.04) were related to lower
Glx levels. Follow-up analysis of the latter showed that voices that evoked emotional
resistance (i.e., fear, sadness, anger), rather thanbehavioral resistance,was a significant
predictor of reduced glutamate (p= 0.02).
Conclusion: The findings could indicate aberrant glutamatergic signaling, or increased
NMDA-receptor hypoactivity in patients who experience their voices to bemore emo-
tionally negative. Overall, the study provides support for the glutamate hypothesis of
schizophrenia.
KEYWORDS
auditory verbal hallucinations, BAVQ-R, emotional valence, Glutamate, MR spectroscopy,
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1 INTRODUCTION
Auditory verbal hallucinations (AVHs), auditory experiences in the
absence of an external acoustic input (Ford et al., 2012;Hugdahl, 2009;
Waters et al., 2006), are a key symptom in schizophrenia, and are
present in about 70% of the patients (Mueser et al., 1990). This symp-
tom can be a source of great distress, as hallucinations often take form
of voices harassing or commanding the individual to do things against
their will. However, the degree of negative emotional valence varies
to a great extent between patients, and some patients even experi-
ence voiceswith positive andencouraging content (Cavelti et al., 2019).
The degree of negative content of the voices has been shown to be
a major factor to distinguish between clinical and nonclinical voice-
hearers (Daalman et al., 2011; Honig et al., 1998; see Laroi, 2012 for
a review), and is a predictor of need for care (Honig et al., 1998).
The cognitive theory of AVHs (Chadwick & Birchwood, 1994) sug-
gests that beliefs the patient has regarding the intent of the voice
(malevolence or benevolence) and power of the voice (omnipotence)
are critical for how the patient will handle and cope with the voice
(van der Gaag et al., 2003). Further, the intent and power of the voice
have been found to relate to two main types of emotional and behav-
ioral responses. Patients who experience benevolent voices tend to
engage with the voice by actively seeking and complying with inten-
tions of the voice, while patients who report their voice to be of malev-
olent intent attempt to resist the voice througharguing andnoncompli-
ance (Chadwick&Birchwood, 1994). The beliefs about voice-intent are
often, but not always, related to the content of the voice. For example,
a voice could be harsh, but the patient still believes itwould look out for
him/her (van der Gaag et al., 2003). Therefore, beliefs about voice con-
tent could arguably be even more tightly linked to distress than voice
content in itself (Chadwick & Birchwood, 1994; Peters et al., 2011).
The Beliefs About Voices Questionnaire (BAVQ (Chadwick & Birch-
wood, 1995), and the revised version, BAVQ-R (Chadwick et al., 2000),
are self-report questionnaires that were developed to assess beliefs,
feelings, and behavior related to AVH contents. The BAVQ-R question-
naire consists of five subscales. Two subscales measure voice intent,
the Malevolence and Benevolence subscales. Another subscale, the
Omnipotence scale, captures how powerful the patient experiences
the voice to be. In addition, the BAVQ-R includes two additional sub-
scales, Resistance and Engagement, which capture the patient’s rela-
tionship to the voice, that is, how the patient responds emotionally and
behaviorally to the voice.
Malevolent voices are often associated with a resistive coping style,
while benevolent voices are associated with an engaging coping style
(Sayer et al., 2000). Based on factor analysis Strauss et al. (2018) sug-
gested that malevolence and omnipotence are in essence overlapping,
and hence suggested a two-factor structure, called persecutory and
benevolent beliefs—where the former can be argued to be character-
ized as unpleasant and of negative emotional valence, while the latter
as more pleasant and of positive emotional valence. However, whether
the degree of malevolence, omnipotence, and resistance on the one
hand, and benevolence and engagement on the other hand, also relate
to differences in the underlying neurobiology of AVHs is currently
unknown.
Accumulating evidence suggests that glutamatergic dysfunction
could play a role in the etiology of schizophrenia, and glutamate has
in several studies been associated with symptom severity (see Merritt
et al., 2013 for a review). A fewstudies have investigated glutamate and
Glx (the sum of glutamate+glutamine) in relation to AVHs using mag-
netic resonance spectroscopy (1H-MRS), an in vivo method that takes
advantageof themagnetic properties of thehydrogenproton (deGraaf,
2007) to assess metabolite levels in brain tissue. Glx is often reported
as glutamate and glutamine are difficult to separate accurately. It is
usually glutamate that contribute the most to the Glx signal (Ramadan
et al., 2013). Previous findings suggest that elevated Glx levels in the
left superior temporal gyrus (STG) (Hjelmervik et al., 2020; Hugdahl
et al., 2015), and inferior frontal gyrus (IFG) (Curcic-Blake et al., 2017;
Hugdahl et al., 2015) are associated with AVH severity (see also Jardri
et al., 2016). Hjelmervik et al. (2020) also found a negative association
for Glx and AVH severity in the ACC. These findings were interpreted
as reflecting STGhyper- andACChypo-activity, as has also been shown
for fMRI (Hugdahl et al., 2009; Jardri et al., 2016). Previous studies
relied on the Positive and Negative Syndrome Scale (PANSS) P3 item
to assess AVH severity (e.g., Hjelmervik et al., 2020; Hugdahl et al.,
2015). However, a limitation is that the PANSS scale does not allow for
data on voice intent, emotional and behavioral coping strategies, with
the result that these factors have not previously been investigated in
relation to glutamate and Glx. Having established that Glx could medi-
ate AVH, a natural next step in this research is therefore to investi-
gate more specific aspects of AVH, such as emotional valence. Since,
fMRI-studies of emotional content of real voices suggest overlapping
brain regionswith those for auditory hallucinations, including temporal
(STG) and frontal (ACC and IFG) regions (Bestelmeyer et al., 2017), one
could hypothesize that glutamate in these regions is also associated
with voice intent and emotional valence of the voices. Although a previ-
ous MRS study from our laboratory did not find associations between
AVH and Glx in right STG (Hjelmervik et al., 2020), this region is par-
ticularly related to processing of affective/emotional aspects of speech
(Mitchell & Crow, 2005), and hence a target region to investigate with
regards to emotional valence of AVH.
The current study aimed to investigate the relationship between
self-experienced and self-reported aspects of AVHs, as measured with
the BAVQ-R questionnaire, and glutamate levels, as measured with
MRS. Following previous fMRI and MRS studies of AVH frequency
and severity, four brain-regions were investigated, namely left and
right STG, left IFG, and ACC (Curcic-Blake et al., 2017; Hjelmervik
et al., 2020; Hugdahl et al., 2015; see also Jardri et al., 2016 for an
overview). From the studies by Strauss et al. (2018) and Sayer et al.
(2000) we expected that the BAVQ-RMalevolence, Omnipotence, and
Resistance subscales (voices of negative emotional valence) and the
Benevolence and Engagement subscales (positive emotional valence),
would be inversely related to Glx levels, respectively. One could fur-
ther hypothesize a regional dependency (Hjelmervik et al., 2020; Jardri
et al., 2016), where voices of more negative emotional valence are
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TABLE 1 Patient information andmedication details
n M (SD)
Illness onset age 33 22.21 (5.84)
Illness duration 33 4.24 (7.36)
Smoking 21
Medicated AP 35 DDD: 0.92 (0.68)
Medication use> 1 year 16
Medication use< 9mnds 9






Note: The dosages of the antipsychotics used were converted to defined
daily doses, which is the assumed average maintenance dose per day for a
drug used for itsmain indication in adults (WHOCC -Definition and general
considerations).
Abbreviation: AP, antipsychotic medication.
positively related to Glx in language regions (Hjelmervik et al., 2020;
Hugdahl et al., 2015); and negatively related to Glx in the ACC
(Hjelmervik et al., 2020).
2 METHODS
2.1 Participants
Thirty-seven schizophrenia patients (mean age 26.84 years, SD
8.65; 11 women, and 26 men) underwent MRS scanning. The
patients were recruited from the Division of Psychiatry, Hauke-
land University Hospital in Bergen, and surrounding local psy-
chiatric outpatient clinics. The patients were diagnosed with
schizophrenia spectrum disorder according to the ICD-10 diag-
nostic manual (World Health Organization, 1992; Norwegian trans-
lation; https://ehelse.no/standarder-kodeverk-og-referansekatalog/
helsefaglige-kodeverk/kodeverket-icd-10-og-icd-11). Diagnoses
were based on the structured clinical interview for DSM-IV Axis I
Disorders (SCID-I) conducted by trained physicians/psychiatrists
and psychologists. The diagnoses were converted to ICD-10 diag-
noses. All patients that were on medication used second-generation
antipsychotic medication, or second-generation in combination with
first-generation antipsychotics (see Table 1 for more details on med-
ication use and illness). Global severity of symptoms in the patient
group as assessed by the PANSS (Kay et al., 1987) total score were
70.73, SD 14.84 (Positive-total 18.24, SD 4.71; Negative-total 16.49,
SD 4.74; General-total 36.00, SD 8.81).Most patients reported to have
elementary school education (n = 21), while some had high school
(n = 9), or college/university education (n = 7). To be included in the
study, patients had to score 2 or higher on the PANSS P3 item. In
addition, the physicians/psychiatrists performing the PANSS interview
made an evaluation as to whether the patient experienced auditory
hallucinations and included those who did. Two MRS data collection
protocols, including varying voxel placements, were used. One pro-
tocol (hereafter referred to as Protocol 1) included MRS recordings
from the left and right STG and ACC and was used in 22 patients.
The next protocol (hereafter referred to as Protocol 2) included MRS
recordings from the left STG and left IFG and was used in 15 patients
(see Figure 1). Data from the two protocols was pooled. The sample
included in the study is a subsample of patients from a larger study
(Beresniewicz et al., 2021; Hjelmervik et al., 2020;Weber et al., 2021).
The current sample (n = 37) made up ≈50% of the patients compared
to the full sample (n = 76: unique subjects) in Hjelmervik et al. (2020).
Themean PANSS P3 score for the current study sample was 3.62 (1.48
SD) in comparison to 2.64 (1.66 SD) in Hjelmervik et al. (2020). The
difference in mean P3 score is mainly due to the exclusion of patients
having P3 scores below 2 in the current study.
The study was approved by the Regional Committee for Medical
Research Ethics at the University of Bergen (REK no 2016/800) and
conducted according to the Declaration of Helsinki. All participants
received oral and written information about the study before signing
a written consent form.
2.2 Beliefs about voices questionnaire (BAVQ-R)
The BAVQ-R questionnaire (Chadwick et al., 2000) was administered
to the patients prior to MRS scans. This questionnaire consists of 35
items that are rated on a four-point scale from “disagree” ( = 0) to
“strongly agree” ( = 3). There are six statements for each of the three
sub-scales that are related to beliefs about voices; Malevolence scale
(e.g., “My voice wants to harm me”); Benevolence scale (e.g., “My voice
wants to protect me”); and Omnipotence scale (e.g., “My voice is very
powerful”). In addition, the questionnaire includes nine and eight state-
ments, respectively, for the Resistance and Engagement sub-scales,
which concerns how the patients relate to and cope with their voices.
Each of these two sub-scales is further subdivided into an emotional
component (Emotional Resistance e.g., “My voice frightens me”; Emo-
tional Engagement e.g., “Myvoice reassuresme”) and abehavioral com-
ponent (Behavioral Resistance e.g., “When I hear my voice, usually I
tell it to leaveme alone”; Behavioral Engagement e.g., “When I hear my
voice, usually I listen to it because I want to”). Patients that experience
more than one voice, are instructed to complete the questionnaire for
their “dominant voice.”
2.3 MR Image acquisition
A 3T GE-Signa MRI scanner was used for data collection. First, an
anatomical T1-weighted image was acquired of each subject (3D
Enhanced Fast Gradient Echo (EFGE3D sequence). For Protocol 1,
the following parameters were used: Repetition time (TR)/echo time
(TE)/flip angle (FA)/field of view (FOV) 7.8ms/2.9ms/14◦/256mm, 256
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F IGURE 1 MRSmeasurements were conducted in four cortical regions, here displayed in sagittal view: The anterior cingulate cortex (ACC),
the left inferior frontal gyrus (L IFG), the left superior temporal gyrus (L STG), and the right superior temporal gyrus (R STG). The red, orange, and
green contours represent 95%, 50%, and 5% confidence regions respectively for voxel placement across the entire group
× 256 scan matrix, 188 sagittal slices, voxel size 1 × 1 × 1 mm). For
Protocol 2, a TR of 3.0, TE of 6.8, and FA of 12 was used, otherwise
parameters were the same as for Protocol 1. Thereafter, MRS acqui-
sition was performed. In Protocol 1, short echo time 1H-spectra were
obtained from the left and the right STG (voxel size 24 × 40 × 30 mm)
and ACC (voxel size 40 × 40 ×25 mm) by using a single-voxel point-
resolved spectroscopy (PRESS) sequence (TE/TR = 35 ms/1500, 128
repetitions). Protocol 2 contained acquisitions from the left STG (voxel
size 24 × 30 ×31 mm) and left IFG (24 × 38 × 28 mm) obtained by
using a PRESS sequence with identical parameters as for Protocol 1
except for left STG voxel-size. Unsuppressed water reference spectra
(eight repetitions) were acquired automatically after the acquisition
of water-suppressed metabolite spectra in both protocols. Center-of-
mass for the voxel localization, given inMontreal neurological Institute
(MNI) space x, y, z coordinates was for the ACC: 0.389, 25.4, 33.9 mm,
left IFG:−36.8, 18.9, 11.9mm, left STG:−48.3,−35.9, 6.02mm, and for
the right STG: 50.2,−34.2, 6.11mm. Between Protocol 1 and 2, a scan-
ner upgrade was conducted that included a change of head-coil from 8
to 32 channels.
2.4 Data analysis
MRS data were analyzed using the LCModel version 6.3-1J
(Provencher, 1993) software. A standard basis-set was used, includ-
ing components from 15 metabolites (Alanine, Aspartate, Creatine,
γ-aminobutyric acid (GABA), Glucose, Glutamine, Glutamate, Glyc-
erophosphorylcholine, Phosphorylcholine, Lactate, myo-inositol,
N-acetylaspartate, N-acetyl-aspartate-glutamate, scyllo-inositol, and
Taurine. Default baseline parameters and a default set of simulated
macromolecule components were included to model background
signal underlying the metabolite spectrum. The estimates of the
metabolites were thereafter scaled to an internal water reference.
Adjustments were made to account for differing water concentration
in the different tissue classes, partial volume effects, metabolite
relaxation times and differing water relaxation times between the
tissue classes, using the formula of (Gasparovic et al., 2006). The seg-
mentation tool of the Statistical Parametric Mapping (SPM8) software
(www.fil.ion.ucl.ac.uk/spm) was used to extract information on tissue
content within the spectroscopy voxel on the basis of the T1 image.
A local quality control procedure identified three spectra (two from
the right STG and one from ACC) that were excluded from further
analysis.Multiple factorswere considered in the assessment of spectra
quality: Signal-to-noise ratio (SNR), spectral linewidth (FWHM; see
Table 2), and CRLB %SD of estimates for key metabolites, in addition
to assessment of variance and magnitude of features in the residuals
after fitting, and magnitude of aberrant features in the spectrum
(relative to group mean spectrum). The resulting quality score flagged
spectra of concern, that were subject to further visual scrutiny of the
fit and residuals, to identify spectra which were of insufficient quality
for meaningful assessment. For further details on analysis procedure,
see Hjelmervik et al. (Hjelmervik et al., 2020; 2018). In the current
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TABLE 2 Concentrationmeans and standard deviations of Glx,
glutamate, glutamine (institutional units), and data quality parameters
in the four cortical regions
N Mean SD
Left STG Glutamate 34 13.43 2.01
Glutamine 34 3.97 2.81
Glx 37 16.52 3.88
Glx CRLB 37 7.27 1.82
SNR 37 37.95 12.69
FWHM (Hz) 37 8.57 2.56
Left IFG Glutamate 15 14.52 1.90
Glutamine 15 3.19 2.24
Glx 15 17.33 3.66
Glx CRLB 15 6.60 1.45
SNR 15 46.33 8.28
FWHM (Hz) 15 7.06 1.57
ACC Glutamate 19 16.65 1.80
Glutamine 19 3.79 2.07
Glx 22 19.58 2.88
Glx CRLB 22 6.32 1.13
SNR 22 41.64 6.30
FWHM (Hz) 22 8.03 1.95
Right STG Glutamate 18 16.16 1.91
Glutamine 18 7.38 4.26
Glx 21 21.55 4.50
Glx CRLB 21 6.14 1.56
SNR 21 33.57 9.70
FWHM (Hz) 21 9.32 2.59
Abbreviations: ACC, anterior cingulate cortex; L IFG, left inferior frontal
gyrus; L STG, left superior temporal gyrus; R STG, right superior tempo-
ral gyrus; SNR, signal-to-noise ratio; FWHM, full-width at half maximum
(linewidth). There is a difference inN betweenGlx and glutamate/glutamine
due to cases where the composite signal was inseparable.
study the combined measure of glutamate and glutamine (Glx) levels
was reported (see Table 2).
2.5 Statistical analysis
Glx values were subjected to statistical analysis using Lin-
ear mixed models available in the SPSS software package
(https://www.ibm.com/analytics/spss-statistics-software). Five
multivariate models were applied to the data in order to test the linear
relationship between regional Glx and emotional valence of AVHs.
In these models, Glx served as dependent variable, brain Region was
entered as a repeated fixed factor, and the BAVQ-R sub-variables
Malevolence, Benevolence, Omnipotence, Resistance, Engagement)
were entered as regressor variables (one for each model). FDR correc-
tion (Benjamini & Hochberg, 1995) was done to control for multiple
comparisons (https://www.webcitation.org/5s004b7CI (webcita-
tion.org); Pike, 2011), and adjusted p-values are reported in addition to
the uncorrected p-values. In order to control for the scanner up-grade,
thiswas included as a covariate dummyvariable in eachof the analyses.
In addition, participants agewas implemented as a covariate (Marsman
et al., 2013). Effect sizes are reported as unstandardized beta values.
3 RESULTS
Multivariate analyses were conducted for each BAVQ-R sub-scale (see
Figure 2).
In the first analysis, a significant main-effect of Omnipotence
(F(1,53.39) = 7.88, p = .01, FDRcorr p = 0.04, B = −1.92) was
found, reflecting a negative association between Omnipotence and
Glx across brain regions. Further, there was a significant main-effect
for the sub-scale Resistance (F(1,53.13) = 6.02, p = .02, FDRcorr
p = 0.04, B = −1.33), suggesting a significantly negative association
between Resistance and Glx levels across regions. As the Resistance
sub-scale consists of both a behavioral component (questions address-
ing responses to the perceived voice intentions) and an emotional com-
ponent (questions addressing emotional responses), post-hoc analyses
were conducted by splitting the Resistance factor. Only the emotional
component (F(1,52.85) = 7.06, p = .01, FDRcorr p = 0.02, B = −.67)
was found significantly associated with Glx. There were no signifi-
cant effects (after FDR correction) for the sub-scales Malevolence
(F(1,44.77) = 4.33, p = .04, FDRcorr p = 0,07, B = −.89), Benevolence
(F(1,31.46) = .85, p = .36, FDRcorr p = 0.45, B = −1.07) and Engage-
ment (F(1,32.42) = .15, p = .70, FDRcorr p = 0.70, B = −.09). For the
latter analysis a main-effect of Region (F(3,46.36) = 2.85, p = 0.05)
was found, reflecting higher levels in the right as compared to the left
STG.Moreover, no furthermain effects of Region or interaction effects
between Region and the BAVQ-R sub-scales were found significant for
any of the analyses. The covariate variables controlling for the change
of coil (all p < 0.02) and Age (all p < 01) were found significant in all
analyses.
4 DISCUSSION
The current study investigated self-reported emotional valence of
AVHs in relation to glutamate levels (measured as Glx) in temporal and
frontal brain regions. The results showed that voices experienced to be
omnipotent, and which the patients resisted, were negatively associ-
ated with Glx levels. This was found across all four brain regions (see
Figure 2). Further exploration of the resistance factor with post hoc
analyses showed that itwas theemotional component of the resistance
sub-scale (e.g., feeling of anxiety or fear in relation to the voice) that
was driving the significant effect.
The expected findings of the study were partly confirmed. Indeed,
significant relationships were found between Glx and the negative
emotional valence sub-scales omnipotence and emotional resistance.
However, the prediction of a reversed relationship between Glx and
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F IGURE 2 Graphs illustrating relations between Glx (y-axis) and the BAVQ-R sub-variables (x-axis) omnipotence, and resistance across the
four cortical regions ACC, left IFG, left STG, and right STG. Note that relationships between variables are illustrated using fixed predicted values
from the LMMs (y-axis). Abbreviations: ACC, anterior cingulate cortex; IU, institutional units; L IFG, left inferior frontal gyrus; L STG, left superior
temporal gyrus; R STG, right superior temporal gyurs;
benevolence and engagement did not come through. This suggests that
it is the negative emotional valence of AVH that is of essence, where
those patients who experienced voices that were omnipotent and that
evoke emotional resistance showed reduced Glx levels across frontal
and temporal brain regions. While previous studies have identified a
relationship between Glx and severity of AVHs (e.g., Hjelmervik et al.,
2020; Hugdahl et al., 2015), the current study adds to this knowl-
edge by suggesting an association betweenGlx and negative emotional
valence of the voices, as experienced and reported by the patient. The
fact that all three negative valence sub-scales, Omnipotence, Resis-
tance, and Malevolence (not significant after correction), were nega-
tively associated with Glx, suggests high internal consistency in the
data and strengthens the credibility of the results.
The hypothesis that the relationship between emotional valence
of AVH and Glx would be dependent on region, was not confirmed.
Instead, reduced Glx levels in relation to negative emotional valence
were found across all four regions. Previous findings have shown
reduced Glx in the ACC in patients with increasing AVH severity
(Hjelmervik et al., 2020). The current finding that reduced ACC Glx is
associated with increased negative emotional valence would support
this finding. However, the current finding of reduced Glx with more
negative emotional valence also in the left STG, could be argued to
stand in contrast to previous findings that suggest an increase in left
STGGlxwith increasingAVHseverity (Hjelmervik et al., 2020;Hugdahl
et al., 2015). Thedifference inAVHmeasurement (PANSSP3vs. BAVQ-
R) could explain this discrepancy. Hjelmervik et al. (2020) suggested
that patients had generally reduced STG “baseline” glutamate levels
relative to controls (Bustillo et al., 2020), which again, for hallucinating
patients, rose to normal levels by the neuronal activity associated with
the AVHs (Hjelmervik et al., 2020). Characteristics picked up by the P3
scale, such as frequencies and loudness of voices, might be driving this
neuronal activity (and thereby the Glx levels) to a larger extent than
the emotional valence in the voices. It has for example been shown in
other studies that emotionally negative content of real voices does not
cause higher neuronal activity in auditory cortical regions than positive
content (Bestelmeyer et al., 2017). It could also be that BAVQ picks up
on a potentially underlying phenomenon such as the emotional state of
the patient, for example, depression or anxiety (Chadwick et al., 2000;
Mawson et al., 2010), which again relates to reduced Glx. In this con-
nection it is interesting to mention that reduced Glx has been found
in depression using meta-analytical approaches (Luykx et al., 2012). In
trait depression Glx levels in ACC was found reduced, but also during
depressive episodes where reduced Glx was found in multiple brain
regions. This suggests that state-dependent fluctuations in glutamate
signalingmaybe present during depression. Finally, it should be consid-
ered that sample differences in the two studies could explain the dif-
ferences in findings, that is, that the current sub-sample might not be
representative for the full sample inHjelmervik et al. (2020). For exam-
ple, in the current study only hallucinating patients (PANSS P3= /> 2)
were included, whereas Hjelmervik et al. (2020) included a significant
portion of nonhallucinating patients. Removing patients at the extreme
end of the scale (P3 scores of 1) could affect the regression line.
What underlying cellular mechanism may be related to reduced
Glx-levels in association with negative emotional valence can at
present only be a matter of speculation. Metabolic cycles of glutamate
(Bak et al., 2006; Gaisler-Salomon et al., 2009) could be affected, or
as commonly suggested, reduced glutamate could be a consequence
of NMDA-receptor hypofunction (Marsman et al., 2013). The latter
explanation is in line with findings of induced schizophrenia-like symp-
toms from ketamine and other NMDA-receptor antagonists (Adler
et al., 1999; Krystal et al., 1994; Lahti et al., 2001). Similarly, the cur-
rent results could be interpreted in terms of more pronounced NMDA
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hypofunction in the patients experiencing emotionally negative voices,
resulting in generally reduced inter-neuronal signal transmission. As
a result of NMDA hypofunction, Glx levels might be downregulated
through a negative-feedback mechanism, or through an excita-
tory/inhibitory imbalance which in the long run can lead to neurotox-
icity, graymatter atrophy and reduced Glx levels (Plitman et al., 2014).
The reduced Glx levels as a function of negative emotional valence
inAVHappear tobe a global rather than a region-specific phenomenon.
This indicate that the findings point to a more basic/underlying neu-
ropathology of the disease (as discussed above) related to negative
emotional valence. This could involve hypofunction of prefrontal cor-
tical regions, in particular the ACC (Minzenberg et al., 2009) accom-
panied with reduced executive functions (Carter et al., 1996; Hugdahl
et al., 2013) Impaired executive control has repeatedly been demon-
strated in schizophrenia, and has been suggested to result in failure
to suppress AVHs arising bottom-up from language regions (Hugdahl,
2009). Similarly, in the current study, reduced ACC Glx could cause
neuronal hypoactivity and a failure to cognitively control AVH. In this
sense, the patients’ experiences of voice omnipotence and emotional
resistance could be a reflection of the loss of control. It should also be
noted that ACC is involved in emotion regulation through inhibitory
signals to the amygdala (Jhang et al., 2018). Future studies aiming to
address the relationship between negative emotional valence of voices
and brain chemistry should therefore attempt to measure Glx also in
the amygdala. The finding that emotional valence of AVHs predicts
Glx-levels, and hence glutamate levels, could be relevant for the idea
of deep phenotyping of patients’ symptoms as suggested by Sommer
et al. (2018). According to this idea, it would be of essence to identify
symptoms that could act as predictors for underlying psychopathology
which, down the road, could be informative in tailoring individual treat-
ment.
5 LIMITATIONS
A few limitations of the study need to be addressed. First, a change
of head-coil was implemented during data collection resulting in data
being collected with two different coils. The change of head-coil might
have altered the accuracy in measurement of Glx: SNR and linewidth
were somewhat improved after this change. It is, however, unlikely
that such a change would impact the relationship between Glx and
negative valence of AVH that was observed in the study. Neverthe-
less, the inclusion of coil as a covariate should have controlled for
any systematic effect on Glx levels. Second, additional variables could
potentially have influenced the results bymodifying Glx levels (Merritt
et al., 2021), includingmedication variables such asmedication type(s),
dosage, response, duration/medication onset. We cannot exclude that
such variables have impacted the results, however, a quick analysis
of medication dosage against regional Glx levels suggested no effect
(p = 0.86). Third, the current study chose to report Glx, as the com-
bined signal of glutamate and glutamine—this could be assessed with
more certainty than the discrete components, therefore allowing us to
include more patients. This comes with the uncertainty as to whether
the results are driven by changes in Glutamate or in glutamine, or both.
6 CONCLUSION
Negative emotional valence of hallucinatory voices has previously
been shown to be an important predictor of illness severity and need
for care in schizophrenia. The current study investigated a potential
role of glutamate in negative emotional valence of AVH. The results
suggest that voices that are believed by the patients to be omnipotent,
and which the patients attempt to emotionally resist, are negatively
related to Glx levels in temporal and frontal brain regions. This might
indicate that high negative emotional valence in voices, as experienced
by schizophrenia patients, is related to anunderlying dysfunction in the
glutamatergic system.
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